At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 124 enrolled
Drug / intervention
Etanercept +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 4 clinical trial evaluating Etanercept and Placebo for Psoriasis. Completed, enrolled 124 participants.
Detailed Summary
The purpose of this study is to determine if etanercept is effective in the treatment of scalp involvement in moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedNov 2008
Primary CompletionJan 2010
Study CompletionMar 2010
TodayJul 2026
First PostedNov 17, 2008
Enrollment StartOct 1, 2008
Primary CompletionJan 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.6 years ago
Interventions
Etanerceptbiological
Etanercept for subcutaneous injection.
Placebobiological
Placebo for subcutaneous injection.